Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips (NYSE:PFE)

The market is red hot this year…or is it?

The S&P 500 (SP500) is up almost 20%, and the Nasdaq 100 (NDX) almost 50%. But in reality, the S&P equal weight is only up 4%.

It’s the S&P 7, while the S&P 493 is flat.

This year, the only thing working well is mega-cap tech.

Pfizer Inc. (NYSE:PFE) is a great example of how it’s always and forever a market of stocks, not a stock market.

PFE is down 40% YTD and has been cut in half off of Pandemic highs.

Why? Was PFE in a massive bubble in recent years? Is the highest yield in 14 years a sign of a value trap? Or the best buying opportunity in a generation?

Here’s a short update on why Pfizer isn’t broken, is a potentially screaming buy…but if you don’t like its risk profile, how to find 9%-yielding blue-chip bargain alternatives that offer more than 4X the superior long-term return potential.

The Perfect Storm Of Negative Growth Headwinds

During the Pandemic, thanks to the COVID-19 vaccine, Pfizer’s earnings grew 196% in two years. Tripling your earnings in 2 years is 73% annual growth, and most start-ups struggle to achieve that. Never mind a company with $13 billion in 2020 net income.

The Covid Vaccine is called Comirnaty.

$38 billion in peak annual sales is a record for any drug in history.

This is still expected to generate $7 billion in annual sales or more going forward, but compared to $38 billion? You can see why Wall Street is a bit upset with Pfizer’s results.

But Pfizer’s bear market isn’t just about earnings falling 76% in 2023.

Long-term analysts expect Pfizer to grow 4% to 5% per year—Moody’s estimates the entire industry will grow earnings by 4% annually.

So, if Pfizer is expected to grow slightly faster than average, why all the hate from investors?

It comes down to the patent cliffs Pfizer is facing in the next few years.

Ibrance is a breast cancer drug that had $5.5 billion in peak sales in 2021 but has a patent cliff of 2027. By the next year, sales of Ibrance are expected to fall to $1.8 billion.

Eliquis is a joint venture heart drug Pfizer developed with Bristol-Myers (BMY) that is expected to see peak sales of $7.4 billion in 2025. And then a 2026 patent cliff means sales by 2028 are expected to fall to $3.3 billion.

The Comps Have Never Looked Worse For Pfizer

Let’s not forget what is taking Wall Street by storm this year.

• AI and GLP-1 obesity drugs.

Look at some of these analyst consensus estimates for obesity drugs.

• Mounjaro (LLY): $20 billion in 2028 sales (2036 patent cliff)
• Wegovy (NVO): $16 billion in 2028 sales (2031 patent cliff)
• Ozempic (NVO too): $21 billion in 2028 sales (2031 patent cliff).

What to do when all Wall Street wants is obesity drugs and Pfizer’s GLP1 drug is an oral medication that hasn’t been approved for obesity and isn’t as effective at rapid weight loss?

Just take a look at Pfizer’s medium-term EPS forecasts.

• 2022: $6.58
• 2023: $1.83
• 2024: $3.20
• 2025: $3.56
• 2026: $3.72
• 2027: $3.70
• 2028: $3.74

That’s 4% EPS growth from 2024 to 2028. Industry average…in a world where Eli Lilly and Novo Nordisk are expected to deliver the following earnings growth.

• LLY 2024 to 2028 EPS growth: 142% (25% annually)
• NVO 2024 to 2028 EPS growth: 78% (16% annually).

Pfizer’s 4% annual growth looks pretty unimpressive compared to the 16% to 25% growth LLY and NVO are expected to deliver.

But is there actually anything wrong with Pfizer’s dividend safety or fundamentals? Nope. The best available data says the company is just fine.

Fundamentals Summary

• yield: 5.5% (3X S&P 500 and above SCHD or VYM)
• dividend safety: 78% safe (2.3% dividend cut risk)
• overall quality: 82% low-risk SWAN
• credit rating: A+ negative outlook (0.6% 30-year bankruptcy risk)
• S&P LT Risk management global percentile: 70th = low risk (good risk management)
• long-term growth consensus: 4.5%
• long-term total return potential: 10.0% vs 10.2% S&P 500
• Current Price: $29.92
• Fair Value: $41.66
• discount to fair value: 28% discount (potential good buy) vs 11% overvaluation on S&P
• 10-year valuation boost: 3.3% annually
• 10-year consensus total return potential: 5.5% yield + 4.5% growth + 5.4% valuation boost = 13.3% vs 9% S&P
• 10-year consensus total return potential: = 249% vs 137% S&P 500.

Yes, Pfizer is expected to recover strongly from the epic collapse in the pandemic COVID vaccine boom.

However, some people don’t want to own pharmaceutical companies because of the specific risk profile of the industry, including patent cliffs and government regulatory risk. So here’s how to find much better 9% yielding alternatives that offer 50% better long-term return potential with equal or better quality and dividend safety.

How To Find 9% Yielding Alternatives To Pfizer Video

Here is how I have used our DK Zen Research Terminal to find the best 9% yielding alternatives to Pfizer.

From 505 stocks in our Master List to the best blue-chip aristocrat bargains.

All in one minute, thanks to the DK Zen Research Terminal. This is how I find all my investment ideas.

	Screening Criteria	Companies Remaining	% Of Master List
1	Blue-Chip Quality (10, 11, 12, and 13 quality scores)	467	93.40%
2	BHS Rating “reasonable buy, good buy, strong buy, very strong buy, ultra value buy”	345	69.00%
3	Non-Speculative (No Turnaround Stocks, investment grade)	303	60.60%
4	5.5+% Yield	31	6.20%
5	11+% Long-Term Return Potential	18	3.60%
6	5 highest yielding PFE alternatives	5	1.00%
Total Time	1 minute

Click to enlarge

9% Yielding Blue-Chip Alternatives To Pfizer

Bottom line up front on these Pfizer alternatives.

Fundamentals Summary

• yield: 8.9% (5X S&P 500 and above SCHD or VYM)
• dividend safety: 85% safe (1.8% dividend cut risk)
• overall quality: 84% low-risk SWAN
• credit rating: A+ negative outlook (0.6% 30-year bankruptcy risk)
• S&P LT Risk management global percentile: 60th = low risk (above-average risk management)
• long-term growth consensus: 5.5% vs 4.5% Pfizer
• long-term total return potential: 14.5% vs 10.2% S&P 500
• discount to fair value: 34% discount (potential very strong buy) vs 11% overvaluation on S&P
• 10-year valuation boost: 4.2% annually
• 10-year consensus total return potential: 8.9% yield + 5.5% growth + 4.2% valuation boost = 18.7% vs 9% S&P
• 10-year consensus total return potential: = 455% vs 137% S&P 500.

And here they are with links to articles with more information and their consensus two-year return potential.

S&P 500

The S&P offers a 20% upside over the next two years if earnings grow as expected (recession risk makes that unlikely) or 9% per year.

These 9%-yielding blue-chip bargains offer 84% two-year return potential or 31% yearly.

4X the market’s return potential in the short term, with 5X the very safe yield.

• Altria Group (MO)
• MPLX (MPLX) – K1 tax form
• British American Tobacco (BTI)
• Physicians Realty Trust (DOC)
• Legal & General Group (OTCPK:LGGNY).

Consensus Total Return Potential Through 2025

• if and only if each company grows as analysts expect
• and returns to historical market-determined fair value
• this is what you will make.

Altria

MPLX

British American

Physicians Realty Trust

Legal & General

S&P 500

The S&P offers a 20% upside over the next two years if earnings grow as expected (recession risk makes that unlikely) or 9% per year.

These 9% yielding blue-chip bargains offer 84% two-year return potential or 31% yearly.

4X the market’s return potential in the short-term, with 5X the very safe yield.

Bottom Line: It’s The Best Time In 14 Years To Buy Pfizer, But Consider These 9% Yielding Alternatives

Pfizer is a wonderful company, and they save lots of lives. In fact, they likely saved millions or possibly tens of millions of people in the Pandemic.

If you’re a fan of Pfizer’s business, it’s the best time in 14 years to buy this company.

If you’re not thrilled by the complex risk profile, including regulatory risk, patent cliffs, and new drug development risk, consider MO, MPLX, BTI, DOC, and LGGNY as faster-growing 9% yielding blue-chip bargains.

With almost double the very safe yield and 1% faster growth than Pfizer is expected to deliver long-term, these five blue-chip bargains offer about 50% superior long-term returns.

• 332% better 30-year inflation-adjusted total return potential

I own about $8,000 worth of Pfizer via ETF and I’m happy to own them. But if I could afford to buy anything right now (family medical emergencies), I would go with BTI as the best risk-adjusted ultra-yield investment opportunity.

BTI is my biggest stock holding and I’m sleeping very well at night.

Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.